(HHT) |
| 0 (0%) 10-12 15:56 |
| Open: | |
| High: | |
| Low: | |
| Volume: | 0 |
| Market Cap: | 0(M) |
| PE Ratio: | 0 |
| Exchange: | |
| Industry: | |
| Sector: |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 39.30 |
| Resistance 1: | 38.12 |
| Pivot price: | 37.66 |
| Support 1: | 36.20 |
| Support 2: | 30.12 |
| 52w High: | |
| 52w Low: |
Financials
| EPS | 2.700 |
| Book Value | 37.120 |
| PEG Ratio | 0.61 |
| Gross Profit | 22.168 |
| Profit Margin (%) | 12.73 |
| Operating Margin (%) | 15.80 |
| Return on Assets (ttm) | 1.1 |
| Return on Equity (ttm) | 7.6 |
Company news
Wed, 07 Oct 2026
From Refractory Iron Deficiency Anemia to the Diagnosis of Hereditary Hemorrhagic Telangiectasia Type 1: A Case Report - Cureus
Wed, 07 Oct 2026
RougeTx Raises $58 Million Series A To Advance HHT Treatment RTX-001 - Pulse 2.0
Wed, 07 Oct 2026
Atavistik Bio to Present at the Cure HHT 16th International Scientific Conference - Yahoo Finance
Tue, 06 Oct 2026
RougeTx launches with $58m Series A to develop a first-in-class HHT treatment - Dealroom
Tue, 06 Oct 2026
RougeTx: Reattaching pericytes to stabilize vessels in HHT - BioCentury Inc.
Tue, 06 Oct 2026
RougeTx launches with $58 million to advance oral HHT candidate toward the clinic - The Pharma Letter
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
